The probabilities of discontinuing treatment (per 8 week cycle) were as follows: during weeks 1-8, 58%, weeks 9-16, 29%, and weeks 17-24, 11%.
The probabilities of relapse and return to acute treatment were as follows: during placebo maintenance 3.98% - 18.07%, during half-dose maintenance 1.44% - 2.46%, and during full-dose maintenance 2.30% - 5.88%.